alpha-aminopyridine has been researched along with Chemotherapy-Induced Febrile Neutropenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arteaga, CL; Beck, JT; Cameron, DA; Conte, P; Germa, C; Hart, LL; Hortobagyi, GN; Jakobsen, E; Lindquist, D; Mondal, S; O'Shaughnessy, J; Petrakova, K; Sonke, GS; Souami, F; Villanueva, C | 1 |
| Lau, G; Palumbo, A; Saraceni, M | 1 |
1 review(s) available for alpha-aminopyridine and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2019 |
1 trial(s) available for alpha-aminopyridine and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Female; Humans; Incidence; Kaplan-Meier Estimate; Letrozole; Leukopenia; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Time Factors | 2018 |